Second-line chemotherapy with paclitaxel and doxifluridine after failure of S-1 in elderly patients with unresectable advanced or recurrent gastric cancer

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 10, 2011, Pages 1499-1504

  Yakabe, Tomomi ^a   Noshiro, Hirokazu ^a   Ikeda, Osamu ^a   Miyoshi, Atsushi ^a   Kitajima, Yoshihiko ^b   Satoh, Seiji ^c  

^a SAGA UNIVERSITY   (Japan)

^b Saga Central Hospital   (Japan)

^c Saga Prefectural Hospital Koseikan   (Japan)

Author keywords

Doxifluridine; Elderly patients; Gastric cancer; Paclitaxel; S 1; Second line chemotherapy

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOXIFLURIDINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GRANISETRON; PACLITAXEL; RANITIDINE;

ADVANCED CANCER; AGE; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSGEUSIA; ELDERLY CARE; FATIGUE; FEVER; HUMAN; HYPOALBUMINEMIA; LEUKOCYTE; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH ADENOCARCINOMA; STOMATITIS; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG COMBINATIONS; FEMALE; FLOXURIDINE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; OXONIC ACID; PACLITAXEL; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TEGAFUR;

EID: 80054760665     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1025-x     Document Type: Article

References (24)

1. CB Begg PP Carbone 1983 Clinical trials and drug toxicity in the elderly. The experience of the eastern cooperative oncology group Cancer 52 11 1986 1992 6354419 10.1002/1097-0142(19831201)52:11<1986::AID-CNCR2820521103>3.0. CO;2-7 1:STN:280:DyaL2c%2Fis1Wjug%3D%3D (Pubitemid 14232235)
2. I Chau AR Norman D Cunningham JS Waters J Oates PJ Ross 2004 Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data J Clin Oncol 22 12 2395 2403 15197201 10.1200/JCO.2004.08.154 (Pubitemid 41121931)
3. N Dong W Jiang H Li Z Liu X Xu M Wang 2009 Triweekly oxaliplatin plus oral capecitabine as first-line chemotherapy in elderly patients with advanced gastric cancer Am J Clin Oncol 32 6 559 563 19581793 10.1097/COC. 0b013e3181967db3 1:CAS:528:DC%2BD1MXhsFShtLnI
4. B Glimelius K Ekström K Hoffman W Graf PO Sjödén U Haglund C Svensson LK Enander T Linné H Sellsröm R Heuman 1997 Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer Ann Oncol 8 2 163 168 9093725 10.1023/A:1008243606668 1:STN:280:DyaK2s3kslGqug%3D%3D (Pubitemid 27112884)
5. Hamaguchi T, Shirao K, Ohtsu A, Hyodo I, Arai Y, Takiuchi H, Fujii H, Yoshida M, Saito H, Denda T, Koizumi W, Iwase H, Boku N (2011) A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial). Gastric Cancer (Epub 2011 Apr 19 ahead of print)
6. S Hironaka S Zenda N Boku A Fukutomi T Yoshino Y Onozawa 2006 Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer Gastric Cancer 9 1 14 18 16557431 10.1007/s10120-005-0351-6 1:CAS:528: DC%2BD28XivVeguro%3D
7. JG Kim BY Ryoo YH Park BS Kim TY Kim YH Im YK Kang 2008 Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy Cancer Chemother Pharmacol 61 2 301 307 17429626 10.1007/s00280-007-0476-x 1:CAS:528:DC%2BD2sXhtlWrs77E (Pubitemid 350160328)
8. Kodera Y, Ito S, Mochizuki Y, Fujitake S, Koshikawa K, Kanyama Y, Matsui T, Kojima H, Takase T, Ohashi N, Fujiwara M, Sakamoto J, Nakao A, FCCC Group (2007) A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 Study). Anticancer Res 27(4C):2667-2671 (Pubitemid 47227980)
9. W Koizumi H Narahara T Hara A Takagane T Akiya M Takagi K Miyashita T Nishizaki O Kobayashi W Takiyama Y Toh T Nagaie S Takagi Y Yamamura K Yanaoka K Orita M Takeuchi 2008 S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 3 215 221 18282805 10.1016/S1470-2045(08)70035-4 1:CAS:528: DC%2BD1cXivVaqtb4%3D
10. W Koizumi T Akiya A Sato K Yamaguchi T Sakuyama N Nakayama S Tanabe K Higuchi T Sasaki T Sekikawa 2009 Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the Gastrointestinal Oncology Group of the Tokyo Cooperative Oncology Group, TCOG GC-0501 trial Jpn J Clin Oncol 39 11 713 719 19812061 10.1093/jjco/hyp099
11. SS Lee JL Lee MH Ryu HM Chang TW Kim HJ Kang WK Kim JS Lee YK Kang 2007 Combination chemotherapy with capecitabine (X) and cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis Jpn J Clin Oncol 37 1 30 37 17272321 10.1093/jjco/hyl134 (Pubitemid 47096440)
12. G Matsuda C Kunisaki H Makino M Fukahori J Kimura T Sato T Oshima Y Nagano S Fuii R Takagawa T Kosaka HA Ono H Akiyama Y Ichikawa 2009 Phase II study of weekly paclitaxel as a second-line treatment for S-1-refractory advanced gastric cancer Anticancer Res 29 7 2863 2867 19596975 1:CAS:528:DC%2BD1MXpslyju70%3D
13. T Moriwaki I Hyodo T Nishina K Hirao T Tsuzuki S Hidaka T Kajiwara S Endo J Nasu S Hirasaki T Masumoto A Kurita 2005 A phase I study of doxifluridine combined with weekly paclitaxel for metastatic gastric cancer Cancer Chemother Pharmacol 56 2 138 144 15827767 10.1007/s00280-004-0983-y 1:CAS:528: DC%2BD2MXksl2hu7s%3D (Pubitemid 40894630)
14. Multiple sites-By year Mortality and Incidence in Japan (2009) Center for Cancer Control and Information Services, National Cancer Center, Japan. Accessed 9 May 2011 http://www.ganjoho.ncc.go.jp/pro/statistics/en/gdb-year.html )
15. J Sakamoto T Matsui Y Kodera 2009 Paclitaxel chemotherapy for the treatment of gastric cancer Gastric Cancer 12 2 69 78 19562460 10.1007/s10120-009-0505-z 1:CAS:528:DC%2BD1MXnvVWqsrY%3D
16. S Sakuramoto K Yamashita M Watanabe 2009 Newly emerging standard chemotherapies for gastric cancer and clinical potential in elderly patients World J Gastrointest Oncol 1 47 54 21160774 10.4251/wjgo.v1.i1.47
17. D Santini F Graziano V Catalano M Seri E Testa AM Baldelli P Giordani A La Cesa B Spalletta B Vincenzi A Russo M Caraglia V Virzi S Cascinu G Tonini 2006 Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial BMC Cancer 6 125 16686939 10.1186/1471-2407-6-125 1:STN:280:DC%2BD28zltFSmtA%3D%3D (Pubitemid 43884147)
18. N Sawada T Nose T Ishikawa T Yutaka 2005 Enhancement of antitumor activity of 5′-deoxy-5-fluorouridine (Furtulon) by taxane in human gastric cancer xenografts Oncol Rep 14 1 53 57 15944767 1:CAS:528:DC%2BD2MXmt1Chtb4%3D
19. Shim HJ, Yun JY, Hwang JE, Bae WK, Cho SH, Chung IJ (2011) Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer. Gastric Cancer 1-8. doi: 10.1007/s10120-011-0032-6
20. K Shitara K Matsuo D Takahari T Yokota T Shibata T Ura S Ito A Sawaki M Tajika H Kawai K Muro 2010 Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel Ann Oncol 21 12 2403 2409 20494962 10.1093/annonc/mdq248 1:STN:280:DC%2BC3cbotFGrug%3D%3D
21. D Takahari Y Shimada S Takeshita H Nishitani A Takashima N Okita Y Hirashima K Kato T Hamaguchi Y Yamada K Shirao 2010 Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer Gastric Cancer 13 3 186 190 20820988 10.1007/s10120-010-0557-0 1:CAS:528:DC%2BC3cXhtFWqsbfP
22. H Takiuchi M Goto H Imamura H Furukawa M Imano H Imamoto Y Kimura H Ishida K Fujitani H Narahara T Shimokawa 2008 Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302) Jpn J Clin Oncol 38 3 176 181 18281707 10.1093/jjco/hyn003 (Pubitemid 351419740)
23. AD Wagner W Grothe J Haerting G Kleber A Grothey WE Fleig 2006 Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data J Clin Oncol 24 18 2903 2909 16782930 10.1200/JCO.2005.05.0245 1:CAS:528:DC%2BD28XntV2gs7s%3D (Pubitemid 46630593)
24. I Yoshimi S Kaneko 2005 Comparison of cancer mortality (all malignant neoplasms) in five countries: France, Italy, Japan, UK and USA from the WHO mortality database (1960-2000) Jpn J Clin Oncol 35 1 48 51 15681606 10.1093/jjco/hyi012 (Pubitemid 40450557)